I Agree

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms of Use.

PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Venture Life Group (VLG)

Venture Life Group

AGM Statement
RNS Number : 7113O
Venture Life Group PLC
03 June 2020
 

3 June 2020

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

AGM Statement

Venture Life   (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, will hold its Annual General meeting ("AGM") this morning as a closed meeting.  At the meeting, the Group's CEO, Jerry Randall, will make the following statement:

 

"Firstly, on behalf of the Board, I must pay tribute to all our incredible employees during the unprecedented challenges that have arisen as a result of COVID-19. Our manufacturing facility in northern Italy has worked tirelessly to maintain our business, our production and supply our customers with minimum disruption. Our commercial team has demonstrated great agility and a strong entrepreneurial spirit, in quickly responding to market demand for sanitising gel, and securing new partnership agreements within a matter of weeks.

 

As outlined on 27th April 2020, we announced the signing of an exclusive €168 million agreement with our existing Chinese partner for a number of the Group's products, including Dentyl, with orders in excess of €7 million for delivery in 2020.

 

With a robust long-term order book, a strong balance sheet and new commercial opportunities, we look forward to updating the market on our progress as the year progresses.

 

The Board would like to thank shareholders for their co-operation and understanding during these challenging and extraordinary times."

 

Venture Life's AGM is being held at 10.30 a.m. this morning as a closed meeting in light of the public health concerns surrounding the COVID-19 pandemic.

 

 

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Andrew Waters, Chief Financial Officer


 

Cenkos Securities plc (Nomad and Broker)

 

+44 (0) 20 7397 8900

Stephen Keys / Mark Connelly / Cameron MacRitchie (Corporate Finance)


Russell Kerr / Michael Johnson (Sales)


 

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.

 

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands, these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies for consumer healthcare products, primarily medical devices.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGMUUAURRRUNRAR
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close